The U.S. Department of Health and Human Services is recommending to the U.S. Drug Enforcement Administration that cannabis should be reclassified as a Schedule III controlled substance under U.S. law, according to a report by Bloomberg on Wednesday. Currently cannabis is a Schedule I drug.
Cresco Labs Inc. CRLBF, +13.73% was rallying by 13.7%, Green Thumb Industries Inc. GTBIF, +19.51% was up by 17.6% and Trulieve Cannabis Corp. TCNNF, +17.28% was up by 15.6%. In a letter to the DEA seen by Bloomberg, Assistant Secretary for Health Rachel Levine cited a Food and Drug Administration review of the drug’s classification.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: